The Indian government has announced the ₹10,000 crore Biopharma SHAKTI scheme to boost domestic production of complex biological medicines. This move aims to transition the pharmaceutical sector from traditional generics to high-value innovation, targeting a 5% global market share in biologics.
The Indian government is launching the Biopharma SHAKTI initiative with a dedicated outlay of ₹10,000 crore to modernize the nation's pharmaceutical manufacturing capabilities. While India is widely recognized as a global leader in generic drug production, this scheme focuses on biologics—medicines derived from living organisms that are significantly more complex to develop and manufacture than traditional chemical drugs.
Targeting High-Value Biologics
The initiative addresses a critical shift in global healthcare demand toward specialized therapies. As chronic diseases increase, the need for advanced treatments such as immunotherapies and precision cancer care has grown. By supporting the development of novel biologics and biosimilars—which are essentially highly similar versions of existing complex drugs—the government aims to help domestic firms enter a high-value market segment. The ultimate goal is to capture 5% of the global biopharmaceutical market, moving beyond the volume-based model of standard generics to innovation-led products.
Scaling CRDMOs and Clinical Research
A primary challenge for Indian companies entering this space is the reliance on expensive foreign infrastructure for specialized research and development. The Biopharma SHAKTI scheme plans to bridge this gap by strengthening the domestic ecosystem for Contract Research, Development, and Manufacturing Organizations (CRDMOs). These organizations provide the essential technical capabilities for biological synthesis and structural characterization required before mass production.
To accelerate the path to market, the scheme includes plans to establish shared high-tech facilities and provide research grants. The government also intends to develop a network of 1,000 clinical trial centers to streamline the testing process. By aligning these efforts with global standards, the government aims to reduce the time for pre-clinical trials to between 2 and 3 years, helping Indian firms compete with established global players.
Strategic Shift and Next Steps
For investors, this scheme represents a long-term strategic push to improve the profit margins and product complexity of Indian pharma companies. The integration of artificial intelligence for drug discovery and the streamlining of regulatory safety processes are key components designed to lower the barriers to entry.
The next important monitorables will be the specific guidelines for fund disbursement, the timeline for setting up the proposed shared research facilities, and which domestic pharmaceutical firms or startups receive the initial grants to scale their development pipelines. Investors will likely track how quickly these companies can successfully navigate the clinical trial process and bring complex biosimilars to both domestic and export markets.